COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01194804
Recruitment Status : Completed
First Posted : September 3, 2010
Results First Posted : July 12, 2019
Last Update Posted : September 17, 2019
CMIC Co, Ltd. Japan
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Brief Summary:
The objective of this study was to assess the long-term safety and efficacy of eculizumab in hemolytic PNH patients who completed the 4-week screening and 12-week treatment period of the C07-001 study. In addition, pharmacokinetic and pharmacodynamic assessments of eculizumab were conducted.

Condition or disease Intervention/treatment Phase
Paroxysmal Nocturnal Hemoglobinuria Drug: Eculizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Extension Study to C07-001 Protocol
Study Start Date : April 2008
Actual Primary Completion Date : September 2010
Actual Study Completion Date : March 2011

Arm Intervention/treatment
Experimental: Eculizumab
Treatment with eculizumab for patients with PNH who have successfully completed the C07-001 protocol
Drug: Eculizumab
Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
Other Name: Soliris

Primary Outcome Measures :
  1. Change From Baseline in Lactate Dehydrogenase [ Time Frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study) ]

Secondary Outcome Measures :
  1. Change From Baseline in FACIT-Fatigue Scale Total Score [ Time Frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study) ]
    The FACIT-Fatigue scale, Version 4.0, is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.

  2. Change From Baseline in PNH Red Blood Cell (RBC) Count [ Time Frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study) ]
  3. Change From Baseline in Number of Units of Packed RBCs Transfused [ Time Frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study) ]
    Baseline is defined as the number of units transfused in 3 months prior to baseline

  4. Change From Baseline in Plasma Free Hemoglobin [ Time Frame: 52 weeks (includes 12 weeks of eculizumab treatment in the parent study and 40 weeks in the extension study) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have fully completed C07-001 study 12-week treatment period

Exclusion Criteria:

  • Patients who terminated early from the C07-001 study
Publications of Results:
Layout table for additonal information
Responsible Party: Alexion Pharmaceuticals Identifier: NCT01194804    
Other Study ID Numbers: E07-001
First Posted: September 3, 2010    Key Record Dates
Results First Posted: July 12, 2019
Last Update Posted: September 17, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alexion Pharmaceuticals:
Hemolytic Paroxysmal Nocturnal Hemoglobinuria
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemoglobinuria, Paroxysmal
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
Anemia, Hemolytic
Hematologic Diseases
Myelodysplastic Syndromes
Bone Marrow Diseases